{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T07:17:00Z","timestamp":1769239020685,"version":"3.49.0"},"reference-count":126,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T00:00:00Z","timestamp":1164931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gastroenterology Clinics of North America"],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1016\/j.gtc.2006.09.008","type":"journal-article","created":{"date-parts":[[2007,1,10]],"date-time":"2007-01-10T15:09:23Z","timestamp":1168441763000},"page":"837-855","source":"Crossref","is-referenced-by-count":74,"title":["Safety of Infliximab and Other Biologic Agents in the Inflammatory Bowel Diseases"],"prefix":"10.1016","volume":"35","author":[{"given":"Jagadeshwar G.","family":"Reddy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Edward V.","family":"Loftus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gtc.2006.09.008_bib1","unstructured":"Remicade (infliximab) for IV injection [prescribing information]. Malvern, PA: Centocor; 2006."},{"issue":"9 Suppl","key":"10.1016\/j.gtc.2006.09.008_bib2","doi-asserted-by":"crossref","first-page":"S311","DOI":"10.14309\/00000434-200509001-00843","article-title":"Maintenance of remission over 1 year in patients with active Crohn's disease treated with adalimumab: results of a blinded, placebo-controlled study","volume":"100","author":"Sandborn","year":"2005","journal-title":"Am J Gastroenterol"},{"issue":"9 Suppl","key":"10.1016\/j.gtc.2006.09.008_bib3","doi-asserted-by":"crossref","first-page":"S316","DOI":"10.14309\/00000434-200509001-00858","article-title":"Remission and clinical response induced and maintained in patients with active Crohn's disease treated for 1-year open-label with adalimumab","volume":"100","author":"Sandborn","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2006.09.008_bib4","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1053\/j.gastro.2005.06.064","article-title":"A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease","volume":"129","author":"Schreiber","year":"2005","journal-title":"Gastroenterology"},{"issue":"Suppl VII","key":"10.1016\/j.gtc.2006.09.008_bib5","first-page":"A82","article-title":"Certolizumab pegol, a humanised anti-TNF pegylated FAb' fragment, is safe and effective in the maintenance of response and remission following induction in active Crohn's disease: a phase III study (Precise)","volume":"54","author":"Schreiber","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2006.09.008_bib6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2006.09.008_bib7","unstructured":"Humira (adalimumab) [prescribing information]. North Chicago, IL: Abbott Laboratories; 2005."},{"key":"10.1016\/j.gtc.2006.09.008_bib8","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa043335","article-title":"Natalizumab induction and maintenance therapy for Crohn's disease","volume":"353","author":"Sandborn","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2006.09.008_bib9","series-title":"User's guides to the medical literature: a manual for evidence-based clinical practice","first-page":"81","article-title":"Harm","author":"Levine","year":"2002"},{"issue":"Suppl 3","key":"10.1016\/j.gtc.2006.09.008_bib10","doi-asserted-by":"crossref","first-page":"S194","DOI":"10.1086\/429996","article-title":"Reactivation of latent granulomatous infections by infliximab","volume":"41","author":"Wallis","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"9 Suppl","key":"10.1016\/j.gtc.2006.09.008_bib11","doi-asserted-by":"crossref","first-page":"S306","DOI":"10.14309\/00000434-200509001-00829","article-title":"Comparison of safety and mortality of infliximab therapy to immunomodulator therapy in Crohn's disease: a cohort study","volume":"100","author":"Doumit","year":"2005","journal-title":"Am J Gastroenterol"},{"issue":"4 Suppl2","key":"10.1016\/j.gtc.2006.09.008_bib12","first-page":"A71","article-title":"Risk factors for opportunistic infections in inflammatory bowel diseases: a case control study","volume":"130","author":"Toruner","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2006.09.008_bib13","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/art.21568","article-title":"Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy","volume":"54","author":"Wolfe","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gtc.2006.09.008_bib14","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cgh.2006.03.002","article-title":"Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry","volume":"4","author":"Lichtenstein","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2006.09.008_bib15","unstructured":"Enbrel (etanercept) for subcutaneous injection [prescribing information]. Thousand Oaks, CA: Immunex Corporation; 2005."},{"key":"10.1016\/j.gtc.2006.09.008_bib16","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/art.21382","article-title":"Tuberculosis associated with therapy against tumor necrosis factor alpha","volume":"52","author":"Winthrop","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gtc.2006.09.008_bib17","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/rheumatology\/keh567","article-title":"TNF-blocking agents and tuberculosis: new drugs illuminate an old topic","volume":"44","author":"Keane","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.gtc.2006.09.008_bib18","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/gut.2005.076034","article-title":"Preventing TB in patients with Crohn's disease needing infliximab or other anti-TNF therapy","volume":"54","author":"Rampton","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2006.09.008_bib19","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2006.09.008_bib20","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/art.511","article-title":"Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy","volume":"46","author":"Van Den Bosch","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gtc.2006.09.008_bib21","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2006.09.008_bib22","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.20217","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gtc.2006.09.008_bib23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gtc.2006.09.008_bib24","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2006.09.008_bib25","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report","volume":"48","author":"Gomez-Reino","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gtc.2006.09.008_bib26","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1002\/art.21137","article-title":"Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden","volume":"52","author":"Askling","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gtc.2006.09.008_bib27","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/art.20009","article-title":"Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gtc.2006.09.008_bib28","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2006.09.008_bib29","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","volume":"38","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.gtc.2006.09.008_bib30","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1086\/424455","article-title":"Granulomatous infections due to tumor necrosis factor blockade: correction","volume":"39","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.gtc.2006.09.008_bib31","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1086\/424457","article-title":"Inconsistencies in reporting of granulomatous infectious disease associated with infliximab and etanercept","volume":"39","author":"Schaible","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.gtc.2006.09.008_bib32","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1086\/424460","article-title":"Tuberculosis cases associated with infliximab and etanercept","volume":"39","author":"Winthrop","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.gtc.2006.09.008_bib33","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0002-9343(02)01205-6","article-title":"Exacerbation of tuberculosis enteritis after treatment with infliximab","volume":"113","author":"Liberopoulos","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.gtc.2006.09.008_bib34","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0002-9343(01)01035-X","article-title":"Exacerbation of Mycobacterium tuberculosis enteritis masquerading as Crohn's disease after treatment with a tumor necrosis factor-alpha inhibitor","volume":"112","author":"Wagner","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.gtc.2006.09.008_bib35","first-page":"683","article-title":"Tuberculosis associated with blocking agents against tumor necrosis factor-alpha\u2014California, 2002\u20132003","volume":"53","author":"Centers for Disease Control and Prevention","year":"2004","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.gtc.2006.09.008_bib36","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1542-3565(04)00060-6","article-title":"High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy","volume":"2","author":"Mow","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2006.09.008_bib37","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2006.09.008_bib38","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","article-title":"Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease","volume":"117","author":"Rutgeerts","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2006.09.008_bib39","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn's disease","volume":"340","author":"Present","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2006.09.008_bib40","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2006.09.008_bib41","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn's disease","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2006.09.008_bib42","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1572-0241.2001.03612.x","article-title":"Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients","volume":"96","author":"Ricart","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2006.09.008_bib43","first-page":"952","article-title":"Clinical outcome of Crohn's disease treated with infliximab","volume":"50","author":"Arslan","year":"2003","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.gtc.2006.09.008_bib44","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","article-title":"The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients","volume":"126","author":"Colombel","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2006.09.008_bib45","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/00054725-200409000-00024","article-title":"Fatal staphylococcal sepsis in Crohn's disease after infliximab","volume":"10","author":"Herrlinger","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gtc.2006.09.008_bib46","first-page":"7","article-title":"Infliximab for Crohn's disease in clinical practice: the experience of a single center in Romania","volume":"12","author":"Gheorghe","year":"2003","journal-title":"Rom J Gastroenterol"},{"key":"10.1016\/j.gtc.2006.09.008_bib47","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1002\/art.10374","article-title":"Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases","volume":"46","author":"Gluck","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gtc.2006.09.008_bib48","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/00005176-200204000-00018","article-title":"Listeria meningitis after treatment with infliximab","volume":"34","author":"Kamath","year":"2002","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.gtc.2006.09.008_bib49","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1572-0241.2003.07161.x","article-title":"Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center","volume":"98","author":"Stephens","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2006.09.008_bib50","first-page":"1470","article-title":"Meningitis due to Listeria monocytogenes as a complication of infliximab therapy","volume":"147","author":"Joosten","year":"2003","journal-title":"Ned Tijdschr Geneeskd"},{"key":"10.1016\/j.gtc.2006.09.008_bib51","first-page":"2145","article-title":"Meningitis due to Listeria monocytogenes as a complication of infliximab therapy","volume":"147","author":"Keulen","year":"2003","journal-title":"Ned Tijdschr Geneeskd"},{"key":"10.1016\/j.gtc.2006.09.008_bib52","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1136\/gut.2003.018515","article-title":"Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County","volume":"53","author":"Ljung","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2006.09.008_bib53","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/art.10758","article-title":"Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents","volume":"48","author":"Slifman","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gtc.2006.09.008_bib54","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1002\/art.10583","article-title":"Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept","volume":"46","author":"Lee","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gtc.2006.09.008_bib55","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1164\/rccm.200206-563OC","article-title":"Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy","volume":"167","author":"Wood","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.gtc.2006.09.008_bib56","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1157\/13062892","article-title":"Systemic candidiasis and infliximab therapy","volume":"27","author":"Belda","year":"2004","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2006.09.008_bib57","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/rheumatology\/41.8.951","article-title":"Pneumocystis carinii pneumonia following a second infusion of infliximab","volume":"41","author":"Tai","year":"2002","journal-title":"Rheumatology"},{"key":"10.1016\/j.gtc.2006.09.008_bib58","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/00054725-200407000-00017","article-title":"Pneumocystis jiroveci (carinii) pneumonia following initiation of infliximab and azathioprine therapy in a patient with Crohn's disease","volume":"10","author":"Seddik","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gtc.2006.09.008_bib59","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1023\/B:DDAS.0000042246.58984.98","article-title":"Pneumocystis carinii pneumonia with oral candidiasis after infliximab therapy for Crohn's disease","volume":"49","author":"Kaur","year":"2004","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gtc.2006.09.008_bib60","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/00054725-200409000-00025","article-title":"Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn's disease","volume":"10","author":"Velayos","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gtc.2006.09.008_bib61","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1007\/s00134-003-1867-z","article-title":"Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate","volume":"29","author":"van der Klooster","year":"2003","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.gtc.2006.09.008_bib62","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJM200104053441415","article-title":"Invasive pulmonary aspergillosis associated with infliximab therapy","volume":"344","author":"Warris","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2006.09.008_bib63","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1086\/502250","article-title":"Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: a possible healthcare-associated case?","volume":"24","author":"De Rosa","year":"2003","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.gtc.2006.09.008_bib64","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1086\/377235","article-title":"Disseminated sporotrichosis associated with treatment with immunosuppressants and tumor necrosis factor-alpha antagonists","volume":"37","author":"Gottlieb","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.gtc.2006.09.008_bib65","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1503\/cmaj.1040563","article-title":"Cutaneous nocardiosis complicating management of Crohn's disease with infliximab and prednisone","volume":"171","author":"Singh","year":"2004","journal-title":"CMAJ"},{"key":"10.1016\/j.gtc.2006.09.008_bib66","first-page":"606","article-title":"Pneumonia due to Cryptococcus neoformans in a patient receiving infliximab: possible zoonotic transmission from a pet cockatiel","volume":"49","author":"Shrestha","year":"2004","journal-title":"Respir Care"},{"key":"10.1016\/j.gtc.2006.09.008_bib67","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1007\/s10096-004-1185-6","article-title":"Cavitating pneumonia after treatment with infliximab and prednisone","volume":"23","author":"Arend","year":"2004","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.gtc.2006.09.008_bib68","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/art.20454","article-title":"Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists","volume":"50","author":"Bergstrom","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gtc.2006.09.008_bib69","first-page":"1055","volume":"108","author":"Wiland","year":"2002","journal-title":"Pol Arch Med Wewn"},{"key":"10.1016\/j.gtc.2006.09.008_bib70","doi-asserted-by":"crossref","first-page":"E88","DOI":"10.1086\/425123","article-title":"Cytomegalovirus retinitis in a patient treated with anti-tumor necrosis factor alpha antibody therapy for rheumatoid arthritis","volume":"39","author":"Haerter","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.gtc.2006.09.008_bib71","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1097\/00042737-200212000-00018","article-title":"Disseminated cytomegalovirus infection in Crohn's disease following anti-tumour necrosis factor therapy","volume":"14","author":"Helbling","year":"2002","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2006.09.008_bib72","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/rheumatology\/keh696","article-title":"Infliximab does not activate replication of lymphotropic herpesviruses in patients with refractory rheumatoid arthritis","volume":"44","author":"Torre-Cisneros","year":"2005","journal-title":"Rheumatol"},{"key":"10.1016\/j.gtc.2006.09.008_bib73","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/WNL.53.3.457","article-title":"TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS\/MRI Analysis Group","volume":"53","author":"Anonymous","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.gtc.2006.09.008_bib74","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","article-title":"Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides","volume":"44","author":"Mohan","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gtc.2006.09.008_bib75","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/00054725-200401000-00004","article-title":"Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease","volume":"10","author":"Thomas","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gtc.2006.09.008_bib76","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/01.mcg.0000155126.82171.32","article-title":"Association of anti-tumor necrosis factor therapy with the development of multiple sclerosis","volume":"39","author":"Enayati","year":"2005","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.gtc.2006.09.008_bib77","first-page":"985","article-title":"Retrobulbar optic neuritis associated with infliximab","volume":"120","author":"Foroozan","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.gtc.2006.09.008_bib78","doi-asserted-by":"crossref","first-page":"W34","DOI":"10.7326\/0003-4819-140-8-200404200-00037-w4","article-title":"Retrobulbar optic neuritis associated with infliximab in a patient with Crohn disease","volume":"140","author":"Strong","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.gtc.2006.09.008_bib79","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1136\/bmj.326.7389.579","article-title":"Bilateral anterior toxic optic neuropathy and the use of infliximab","volume":"326","author":"ten Tusscher","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.gtc.2006.09.008_bib80","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/01.SMJ.0000155499.21189.75","article-title":"Infliximab-induced headache and infliximab-induced meningitis: two ends of the same spectrum?","volume":"98","author":"Hegde","year":"2005","journal-title":"South Med J"},{"issue":"7","key":"10.1016\/j.gtc.2006.09.008_bib81","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/ard.2005.043166","article-title":"Safety analyses of adalimumab (Humira) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis","volume":"65","author":"Schiff","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.gtc.2006.09.008_bib82","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1053\/j.gastro.2005.06.022","article-title":"Increased risk for demyelinating diseases in patients with inflammatory bowel disease","volume":"129","author":"Gupta","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2006.09.008_bib83","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1212\/01.WNL.0000142974.81103.95","article-title":"Acute neuropathy with multiple conduction blocks after TNFalpha monoclonal antibody therapy","volume":"63","author":"Singer","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.gtc.2006.09.008_bib84","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1085-9489.2005.00053.x","article-title":"Multifocal motor neuropathy during treatment with infliximab","volume":"10","author":"Cocito","year":"2005","journal-title":"J Peripher Nerv Syst"},{"issue":"Suppl S","key":"10.1016\/j.gtc.2006.09.008_bib85","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.1016\/j.jaad.2005.03.062","article-title":"Distal lower extremity paresthesia and foot drop developing during adalimumab therapy","volume":"53","author":"Berthelot","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.gtc.2006.09.008_bib86","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.gtc.2006.09.008_bib87","doi-asserted-by":"crossref","first-page":"807","DOI":"10.7326\/0003-4819-138-10-200305200-00008","article-title":"Case reports of heart failure after therapy with a tumor necrosis factor antagonist","volume":"138","author":"Kwon","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.gtc.2006.09.008_bib88","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.amjmed.2003.09.039","article-title":"Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy","volume":"116","author":"Wolfe","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.gtc.2006.09.008_bib89","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1097\/00042737-200409000-00022","article-title":"Extensive forearm deep venous thrombosis following a severe infliximab infusion reaction","volume":"16","author":"Ryan","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2006.09.008_bib90","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/j.1572-0241.2003.07368.x","article-title":"Retinal vein thrombosis after infliximab (Remicade) treatment for Crohn's disease","volume":"98","author":"Puli","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"Pt 1","key":"10.1016\/j.gtc.2006.09.008_bib91","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0399-8320(04)95017-8","article-title":"Paroxysmal nocturnal hemoglobinuria revealed by hepatic vein thrombosis (Budd-Chiari syndrome) during Infliximab therapy","volume":"28","author":"Sobkeng Goufack","year":"2004","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.gtc.2006.09.008_bib92","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/art.20311","article-title":"Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gtc.2006.09.008_bib93","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/ard.2004.030528","article-title":"Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas","volume":"64","author":"Geborek","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.gtc.2006.09.008_bib94","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/gut.2004.049460","article-title":"Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine","volume":"54","author":"Kandiel","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2006.09.008_bib95","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jaad.2004.03.047","article-title":"Aggressive cutaneous T-cell lymphomas after TNFalpha blockade","volume":"51","author":"Adams","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"5 Suppl","key":"10.1016\/j.gtc.2006.09.008_bib96","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/j.jaad.2003.11.044","article-title":"Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab","volume":"50","author":"Esser","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.gtc.2006.09.008_bib97","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0016-5085(03)00701-7","article-title":"Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study","volume":"125","author":"Vermeire","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2006.09.008_bib98","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1097\/01.MIB.0000186408.07769.78","article-title":"Infliximab treatment does not induce organ-specific or nonorgan-specific autoantibodies other than antinuclear and anti-double-stranded DNA autoantibodies in Crohn's disease","volume":"11","author":"Nancey","year":"2005","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gtc.2006.09.008_bib99","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1034\/j.1600-0609.2003.00115.x","article-title":"Aplastic anemia following administration of a tumor necrosis factor-alpha inhibitor","volume":"71","author":"Kuruvilla","year":"2003","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.gtc.2006.09.008_bib100","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/rheumatology\/key051","article-title":"Life-threatening reversible bone marrow toxicity in a rheumatoid arthritis patient switched from leflunomide to infliximab","volume":"42","author":"Marchesoni","year":"2003","journal-title":"Rheumatology"},{"key":"10.1016\/j.gtc.2006.09.008_bib101","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1093\/rheumatology\/keg341","article-title":"Pancytopenia in a patient with scleroderma treated with infliximab","volume":"42","author":"Menon","year":"2003","journal-title":"Rheumatology"},{"key":"10.1016\/j.gtc.2006.09.008_bib102","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/rheumatology\/keg338","article-title":"Pancytopenia in a patient with scleroderma treated with infliximab: reply","volume":"42","author":"Marchesoni","year":"2003","journal-title":"Rheumatology"},{"key":"10.1016\/j.gtc.2006.09.008_bib103","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1046\/j.1365-2036.2003.01778.x","article-title":"Drug interaction between infliximab and azathioprine in patients with Crohn's disease","volume":"18","author":"Roblin","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2006.09.008_bib104","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4065\/76.1.84","article-title":"Infliximab-associated reversible cholestatic liver disease","volume":"76","author":"Menghini","year":"2001","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.gtc.2006.09.008_bib105","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1136\/ard.62.9.908","article-title":"Acute, non-obstructive, sterile cholecystitis associated with etanercept and infliximab for the treatment of juvenile polyarticular rheumatoid arthritis","volume":"62","author":"Foeldvari","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.gtc.2006.09.008_bib106","first-page":"1624","article-title":"Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease","volume":"30","author":"Michel","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.gtc.2006.09.008_bib107","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/gut.2004.040675","article-title":"Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis","volume":"53","author":"Esteve","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2006.09.008_bib108","first-page":"608","article-title":"Immunomodulators and \u201con demand\u201d therapy with infliximab in Crohn's disease: clinical experience with 400 infusions","volume":"98","author":"Kinney","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2006.09.008_bib109","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1572-0241.2003.07343.x","article-title":"Infliximab (Remicade) therapy in the treatment of pediatric Crohn's disease","volume":"98","author":"Baldassano","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2006.09.008_bib110","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1111\/j.1572-0241.2004.30186.x","article-title":"Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis","volume":"99","author":"Katz","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2006.09.008_bib111","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2036.2005.02405.x","article-title":"Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease","volume":"21","author":"Mahadevan","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2006.09.008_bib112","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1111\/j.1572-0241.2001.03987.x","article-title":"Infliximab treatment and pregnancy outcome in active Crohn's disease","volume":"96","author":"Srinivasan","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2006.09.008_bib113","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/gut.2005.065417","article-title":"Adalimumab use in pregnancy","volume":"54","author":"Vesga","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2006.09.008_bib114","first-page":"435","article-title":"Term pregnancy in a patient with Crohn's disease under treatment with adalimumab","volume":"28","author":"Sanchez Munoz","year":"2005","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2006.09.008_bib115","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/00054725-200205000-00005","article-title":"Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion","volume":"8","author":"Riegert-Johnson","year":"2002","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gtc.2006.09.008_bib116","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/00054725-200405000-00016","article-title":"Diffuse alveolar hemorrhage after infliximab treatment of Crohn's disease","volume":"10","author":"Panagi","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gtc.2006.09.008_bib117","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1002\/art.10348","article-title":"Bullous skin lesions following infliximab infusion in a patient with rheumatoid arthritis","volume":"46","author":"Kent","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gtc.2006.09.008_bib118","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1345\/aph.1C477","article-title":"Psoriasiform eruption induced by infliximab","volume":"38","author":"Verea","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.gtc.2006.09.008_bib119","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1046\/j.1365-2036.2002.01205.x","article-title":"A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin","volume":"16","author":"Gordon","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2006.09.008_bib120","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1053\/gast.2001.26260","article-title":"A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease","volume":"121","author":"Gordon","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2006.09.008_bib121","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa020732","article-title":"Natalizumab for active Crohn's disease","volume":"348","author":"Ghosh","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2006.09.008_bib122","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","article-title":"Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease","volume":"353","author":"Van Assche","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2006.09.008_bib123","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMoa051782","article-title":"Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis","volume":"353","author":"Kleinschmidt-DeMasters","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2006.09.008_bib124","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","article-title":"Progressive multifocal leukoencephalopathy in a patient treated with natalizumab","volume":"353","author":"Langer-Gould","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2006.09.008_bib125","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa054693","article-title":"Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy","volume":"354","author":"Yousry","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2006.09.008_bib126","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.cgh.2006.05.020","article-title":"Risk and benefits of infliximab for the treatment of Crohn's disease","volume":"4","author":"Siegel","year":"2006","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Gastroenterology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855306000847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855306000847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T17:47:00Z","timestamp":1587318420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889855306000847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":126,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["S0889855306000847"],"URL":"https:\/\/doi.org\/10.1016\/j.gtc.2006.09.008","relation":{},"ISSN":["0889-8553"],"issn-type":[{"value":"0889-8553","type":"print"}],"subject":[],"published":{"date-parts":[[2006,12]]}}}